HRP20010141A2 - Method for administering insulinotropic peptides - Google Patents

Method for administering insulinotropic peptides

Info

Publication number
HRP20010141A2
HRP20010141A2 HR20010141A HRP20010141A HRP20010141A2 HR P20010141 A2 HRP20010141 A2 HR P20010141A2 HR 20010141 A HR20010141 A HR 20010141A HR P20010141 A HRP20010141 A HR P20010141A HR P20010141 A2 HRP20010141 A2 HR P20010141A2
Authority
HR
Croatia
Prior art keywords
glp
molecule
released
val8
patient
Prior art date
Application number
HR20010141A
Other languages
English (en)
Croatian (hr)
Inventor
Benjamin Lee Hughes
Ronald Keith Wolff
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20010141(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HRP20010141A2 publication Critical patent/HRP20010141A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HR20010141A 1998-08-28 1999-08-24 Method for administering insulinotropic peptides HRP20010141A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9827398P 1998-08-28 1998-08-28
US10001298P 1998-09-11 1998-09-11
PCT/US1999/019348 WO2000012116A1 (fr) 1998-08-28 1999-08-24 Procede pour administrer des peptides insulinotropiques

Publications (1)

Publication Number Publication Date
HRP20010141A2 true HRP20010141A2 (en) 2002-02-28

Family

ID=26794577

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010141A HRP20010141A2 (en) 1998-08-28 1999-08-24 Method for administering insulinotropic peptides

Country Status (21)

Country Link
EP (1) EP0997151B1 (fr)
JP (1) JP2002523466A (fr)
KR (1) KR20010073033A (fr)
CN (1) CN1314818A (fr)
AR (1) AR022368A1 (fr)
AT (1) ATE347902T1 (fr)
AU (1) AU764371B2 (fr)
BR (1) BR9913284A (fr)
CA (1) CA2341454A1 (fr)
CO (1) CO5090908A1 (fr)
CZ (1) CZ2001690A3 (fr)
DE (1) DE69934380D1 (fr)
EA (1) EA200100289A1 (fr)
HR (1) HRP20010141A2 (fr)
HU (1) HUP0103369A3 (fr)
IL (1) IL141241A0 (fr)
NO (1) NO20010982L (fr)
PE (1) PE20001031A1 (fr)
PL (1) PL346317A1 (fr)
TR (1) TR200100600T2 (fr)
WO (1) WO2000012116A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU2353701A (en) * 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001264789A1 (en) * 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
GEP20063908B (en) * 2001-10-18 2006-08-25 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2005003296A2 (fr) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Proteines hybrides d'albumine
CA2841097A1 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumine et proteines hybrides g-csf
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
EP1545457A4 (fr) * 2002-08-01 2009-07-01 Mannkind Corp Compositions de transport cellulaire et utilisations
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ 新規なｇｌｐ−１化合物
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
KR100704447B1 (ko) * 2005-05-16 2007-04-09 정용현 3단계로 코팅되는 김치 유산균의 코팅방법 및 그로부터 제조된 코팅된 김치유산균 및 코팅된 김치 유산균이 함유된 조성물
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
PL1965823T3 (pl) * 2005-11-04 2017-08-31 Glaxosmithkline Llc Sposoby podawania środków hipoglikemicznych
WO2007075534A2 (fr) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Conjugues polymeres de glp-1
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
JO2945B1 (en) * 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
WO2008132224A2 (fr) * 2007-04-30 2008-11-06 Novo Nordisk A/S Procédé de déshydratation d'une composition de protéine, composition de protéine déshydratée et composition pharmaceutique contenant la protéine déshydratée
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
KR101736502B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
EP2609954B1 (fr) 2008-06-20 2021-12-29 MannKind Corporation Appareil interactif pour l'établissement en temps réel d'un profil des efforts d'inhalation
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
SI2379100T1 (sl) 2009-01-08 2015-02-27 Mannkind Corporation Zdravljenje hiperglikemije z GLP-1
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (fr) 2012-10-26 2014-05-01 Mannkind Corporation Compositions et procédés de vaccin antigrippal inhalable
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (fr) 2013-08-05 2022-04-26 Mannkind Corporation Appareil d'insufflation et procedes
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
KR102288156B1 (ko) 2017-02-21 2021-08-11 제이에프이 스틸 가부시키가이샤 고탄소 열연 강판 및 그 제조 방법
GB201917723D0 (en) 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
TW202541834A (zh) 2024-04-16 2025-11-01 南韓商韓美藥品股份有限公司 吸入用組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE122009000079I2 (de) * 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6153211A (en) * 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances

Also Published As

Publication number Publication date
IL141241A0 (en) 2002-03-10
TR200100600T2 (tr) 2001-07-23
EA200100289A1 (ru) 2001-10-22
AU764371B2 (en) 2003-08-14
ATE347902T1 (de) 2007-01-15
PL346317A1 (en) 2002-01-28
WO2000012116A1 (fr) 2000-03-09
CA2341454A1 (fr) 2000-03-09
HUP0103369A2 (hu) 2002-02-28
EP0997151A3 (fr) 2000-09-20
AU5584199A (en) 2000-03-21
AR022368A1 (es) 2002-09-04
DE69934380D1 (de) 2007-01-25
HUP0103369A3 (en) 2002-03-28
PE20001031A1 (es) 2000-10-12
JP2002523466A (ja) 2002-07-30
CZ2001690A3 (cs) 2002-04-17
CO5090908A1 (es) 2001-10-30
CN1314818A (zh) 2001-09-26
EP0997151A2 (fr) 2000-05-03
NO20010982L (no) 2001-04-27
NO20010982D0 (no) 2001-02-27
EP0997151B1 (fr) 2006-12-13
BR9913284A (pt) 2001-05-15
KR20010073033A (ko) 2001-07-31

Similar Documents

Publication Publication Date Title
US6720407B1 (en) Method for administering insulinotropic peptides
AU764371B2 (en) Method for administering insulinotropic peptides
US6335316B1 (en) Method for administering acylated insulin
AU747619B2 (en) Method for administering ASPB28-human insulin
EP1173482A1 (fr) Cristaux d'insuline destines a une administration pulmonaire
JP2005506956A (ja) 長時間作用性ｇｌｐ−１製剤
AU5349694A (en) Pulmonary delivery of active fragments of parathyroid hormone
EP1196445A1 (fr) Cristaux d'insuline administres par voie pulmonaire
EP1666054A1 (fr) Méthode d' administration de peptides à activité insulinotropique
HK1029041A (en) Method for administering insulinotropic peptides
MXPA01001905A (en) Method for administering insulinotropic peptides
US20040214747A1 (en) Method for administering monomeric insulin
WO2004054606A1 (fr) Methode de diminution de la production de glucose hepatique chez des patients diabetiques
WO2002009668A2 (fr) Administration de flint (proteine inhibitrice du ligand fas) par voie pulmonaire
CZ20002417A3 (cs) Léčivo pro podávání inhalaci
MXPA00006645A (en) Method for administering aspb28-human insulin
MXPA00006644A (en) Method for administering monomeric insulin analogs
ZA200101541B (en) Method for administering insulinotropic peptides.
CZ20002418A3 (cs) Způsob podávání monomerního analogu inzulínu

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn